Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Gaul

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymesMaurice J van Eis, Jean-Pierre Evenou, Philipp Floersheim, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachChao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitorsMarc Gerspacher, Pascal Furet, Carole Pissot-Soldermann, et al.
Journal of Medicinal Chemistry|November 3, 2020
Evolution of Novartis' Small Molecule Screening Deck DesignAnsgar Schuffenhauer, Nadine Schneider, Samuel Hintermann, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Discovery|June 12, 2012
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependentRita Andraos, Zhiyan Qian, Débora Bonenfant, et al.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of orally available naphthyridine protein kinase D inhibitorsErik L Meredith, Ophelia Ardayfio, Kimberly Beattie, et al.
Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymesMaurice J van Eis, Jean-Pierre Evenou, Philipp Floersheim, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachChao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitorsMarc Gerspacher, Pascal Furet, Carole Pissot-Soldermann, et al.
Journal of Medicinal Chemistry|November 3, 2020
Evolution of Novartis' Small Molecule Screening Deck DesignAnsgar Schuffenhauer, Nadine Schneider, Samuel Hintermann, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Discovery|June 12, 2012
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependentRita Andraos, Zhiyan Qian, Débora Bonenfant, et al.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of orally available naphthyridine protein kinase D inhibitorsErik L Meredith, Ophelia Ardayfio, Kimberly Beattie, et al.
Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Pageof 3